Skip to main content

An official website of the United States government

Pharmaceutical: Acamprosate (36C77025Q0014)

Waiver type - Procurement: Nonavailability

Agency: VETERANS AFFAIRS, DEPARTMENT OF (3600) • Product Service Code (PSC) : 6505 | Last Modified: 11/08/2024

Procurement Summary

The acquisition is for the pharmaceutical Acamprosate CA 333MG EC for six (6) VA CMOP locations. The CMOPs have critically low stock and require this pharmaceutical to fulfill veteran prescriptions in support of their medical needs. The drug is used by patients in support of abstinence from alcohol in patients with alcohol dependence.

Waiver Rationale Summary

The solicitation included FAR 52.225-5 (Trade Agreements) and 52.225-6 (Trade Agreements Certificate) due to the solicitation having an estimated value that exceeded the Trade Agreements threshold, and being unrestricted (open to both large and small business concerns). However, market research found no U.S., or designated country end items. The solicitation confirmed the market research findings as no U.S.-made or designated country end products were quoted. Since only end products from a non designated country were quoted, a nonavailability determination is required per FAR 25.502(b)(3) and 25.103(b)(2).

Did / Will the solicitation include one of the standard BAA provisions announcing the agency’s intention to provide a price preference for domestic end products and construction material?

Yes

Was a sources sought or Request for Information issued?

No

OMB Determination

Consistent with Policy

Product

DRUGS AND BIOLOGICALS

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Date Submitted

10/29/2024

Procurement Instrument Identifier (PIID)

36C77025Q0014

Solicitation ID

36C77025Q0014

Procurement Stage

Post-solicitation

Expected Maximum Duration of the Proposed Waiver

Instant Delivery Only

Waiver Coverage

Individual Waiver

Funding Agency

VETERANS AFFAIRS, DEPARTMENT OF